Literature DB >> 3888367

Combination antiemetic therapy in cisplatin-induced nausea and vomiting.

H B Krebs, M B Myers, J B Wheelock, D R Goplerud.   

Abstract

Twenty-seven consecutive patients with advanced gynecologic malignancies undergoing chemotherapy with cisplatin in combination with other agents were studied in a prospective, randomized fashion to compare the antiemetic efficacy of a combination regimen with high-dose metoclopramide. The combination regimen consisted of prochlorperazine, dexamethasone, and pentobarbital. Patients treated with the combination regimen had significantly less vomitus (P less than 0.01, Student's t test) and fewer vomiting episodes (P less than 0.001, test for homogeneity) than patients treated with metoclopramide. In addition, the sedative and sleep-inducing effect of the barbiturate made the experience of vomiting more tolerable, even in those instances where the combination regimen was not superior to metoclopramide in the control of vomiting.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3888367     DOI: 10.1002/1097-0142(19850601)55:11<2645::aid-cncr2820551119>3.0.co;2-j

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  2 in total

1.  A phase II antiemetic combination (COMD) for cisplatin-induced nausea and vomiting.

Authors:  F Roila; C Basurto; V Minotti; E Ballatori; M Tonato
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

2.  Antiemetic efficacy of high-dose dexamethasone: randomized, double-blind, crossover study with a combination of dexamethasone, metoclopramide and diphenhydramine.

Authors:  H Y al-Idrissi; E M Ibrahim; K A Abdullah; W A Ababtain; H A Boukhary; H M Macaulay
Journal:  Br J Cancer       Date:  1988-03       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.